Beyond studying European genetic structural variation, Estonian Genome Project Director Andres Metspalu envisions using the tens of thousands of samples collected so far to better inform healthcare decisions in Estonia, and sees increasing opportunities to take part in drug development activities.
"If approved by the FDA, the DxS TheraScreen: K-RAS Mutation Kit would become a companion diagnostic for use with Erbitux in metastatic colorectal cancer to determine which patients have wild-type KRAS status in the US," DxS said this week.
A Phase III prospective study shows Vectibix combined with an irinotecan-based chemotherapy regimen improves progression-free survival in patients with wild-type KRAS tumors compared to chemotherapy alone. The study did not reach statistical significance for showing improvement in overall survival, however.
The firm's revenues fell 61 percent, but it cut its net loss 28 percent on lower spending. Decode also cautioned that it has sufficient cash resources to fund its operations only into the second half of its third quarter.